MX2020012797A - Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. - Google Patents

Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.

Info

Publication number
MX2020012797A
MX2020012797A MX2020012797A MX2020012797A MX2020012797A MX 2020012797 A MX2020012797 A MX 2020012797A MX 2020012797 A MX2020012797 A MX 2020012797A MX 2020012797 A MX2020012797 A MX 2020012797A MX 2020012797 A MX2020012797 A MX 2020012797A
Authority
MX
Mexico
Prior art keywords
pvrig
methods
bispecific antibodies
tigit bispecific
tigit
Prior art date
Application number
MX2020012797A
Other languages
English (en)
Spanish (es)
Inventor
Sandeep Kumar
Andrew W Drake
Sayantan Mitra
Adam Salles
Sarah Whelan
Arun Kashyap
Keith Akama
Neha Yevalekar
Carlos Fabricio Santamaria
Original Assignee
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compugen Ltd filed Critical Compugen Ltd
Publication of MX2020012797A publication Critical patent/MX2020012797A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2020012797A 2018-06-01 2019-05-31 Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. MX2020012797A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679703P 2018-06-01 2018-06-01
US201862773586P 2018-11-30 2018-11-30
PCT/US2019/035062 WO2019232484A1 (en) 2018-06-01 2019-05-31 Anti-pvrig/anti-tigit bispecific antibodies and methods of use

Publications (1)

Publication Number Publication Date
MX2020012797A true MX2020012797A (es) 2021-03-25

Family

ID=67003669

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012797A MX2020012797A (es) 2018-06-01 2019-05-31 Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.

Country Status (14)

Country Link
US (1) US20190382477A1 (https=)
EP (1) EP3802605A1 (https=)
JP (2) JP7646361B2 (https=)
KR (1) KR20210016448A (https=)
CN (1) CN113039202A (https=)
AU (1) AU2019276578A1 (https=)
BR (1) BR112020024249A2 (https=)
CA (1) CA3101019A1 (https=)
CL (1) CL2020003127A1 (https=)
CO (1) CO2020016619A2 (https=)
IL (1) IL279053A (https=)
MX (1) MX2020012797A (https=)
SG (1) SG11202011461TA (https=)
WO (1) WO2019232484A1 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
BR112021000727A2 (pt) 2018-07-20 2021-04-13 Surface Oncology, Inc. Composições anti-cd112r e métodos
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
WO2021013068A1 (en) * 2019-07-19 2021-01-28 Wuxi Biologics (Shanghai) Co., Ltd. Polypeptide complex for conjugation and use thereof
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
KR20220154140A (ko) 2020-03-13 2022-11-21 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Pvrig 결합 단백질 및 이의 의학적 용도
CA3176497A1 (en) 2020-05-07 2021-11-11 Fatima MECHTA-GRIGORIOU Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
CN115916348A (zh) 2020-06-18 2023-04-04 基因泰克公司 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
CA3188566A1 (en) * 2020-07-03 2022-01-06 Suzhou Alphamab Co., Ltd. Coagulation factor xi (fxi) binding protein
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
US11028172B1 (en) * 2020-11-10 2021-06-08 Lepu Biopharma Co., Ltd. Anti-TIGIT antibodies and uses thereof
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
EP4284516A1 (en) * 2021-01-28 2023-12-06 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
WO2022165275A2 (en) * 2021-01-28 2022-08-04 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies
EP4292611A4 (en) * 2021-02-09 2025-06-25 Shanghai Junshi Biosciences Co., Ltd. ANTI-CD112R ANTIBODIES AND USE THEREOF
US20240270840A1 (en) 2021-02-11 2024-08-15 Nectin Therapeutics Ltd. Antibodies against cd112r and uses thereof
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
AU2022253351A1 (en) 2021-04-09 2023-10-12 Boehringer Ingelheim International Gmbh New scaffold for bifunctional molecules with improved properties
CN115010800B (zh) * 2021-06-10 2024-08-06 百奥赛图(北京)医药科技股份有限公司 Pvrig基因人源化非人动物的构建方法及应用
EP4588524A3 (en) * 2021-07-01 2025-09-03 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
AU2022320667A1 (en) * 2021-07-30 2024-03-14 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-pvrig/anti-tigit bispecific antibody and application
JP2024535793A (ja) 2021-09-15 2024-10-02 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｐｄ－１に特異的に結合するタンパク質及びその医薬的使用
CN117858903A (zh) 2021-09-15 2024-04-09 江苏恒瑞医药股份有限公司 一种含抗pvrig/tigit双特异性抗体的药物组合物
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
CN114057867B (zh) * 2021-12-14 2023-05-12 河南联科物联网科技有限公司 一种抗减蛋综合征的单克隆抗体及其应用
CN115819582A (zh) * 2021-12-24 2023-03-21 合肥天港免疫药物有限公司 Pvrig的抗体或其抗原结合片段及其应用
CN116925233A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
CN116925222A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pvrig抗体、其药物组合物及用途
EP4537107A2 (en) 2022-06-07 2025-04-16 Genentech, Inc. Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
US20260041765A1 (en) * 2022-06-08 2026-02-12 Shandong Simcere Biopharmaceutical Co., Ltd. Pharmaceutical composition of pvrig/tigit bispecific antibody and use thereof
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
CN120513101A (zh) * 2023-01-19 2025-08-19 山东先声生物制药有限公司 抗pvrig/抗tigit双特异性抗体在治疗恶性肿瘤中的用途
CN120693178A (zh) 2023-03-15 2025-09-23 上海迈晋生物医药科技有限公司 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途
CN121358499A (zh) 2023-03-30 2026-01-16 Ose免疫疗法 靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途
AU2024254671A1 (en) 2023-03-30 2025-10-02 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
EP4724495A1 (en) * 2023-06-06 2026-04-15 WuXi Biologics Ireland Limited Anti-tigit x pvrig antibodies and uses thereof
AU2024288439A1 (en) * 2023-07-07 2026-02-26 D3 Bio (Wuxi) Co., Ltd. Combination therapies for the treatment of cancer
WO2025068452A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025068461A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025132831A1 (en) 2023-12-19 2025-06-26 Universite D'aix-Marseille N-heteroaryl derivatives and uses thereof for treating cancer
CN120230207A (zh) * 2023-12-29 2025-07-01 百奥泰生物制药股份有限公司 Pvrig结合蛋白、双特异性抗体及其应用
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025262250A1 (en) 2024-06-20 2025-12-26 Negio Therapeutics Guanfacine derivatives and their uses
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
CN120058919B (zh) * 2025-04-29 2025-07-18 浙江大学杭州国际科创中心 抗裂谷热病毒Gn蛋白的单抗及在病毒检测中的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US7139665B2 (en) 2002-02-27 2006-11-21 California Institute Of Technology Computational method for designing enzymes for incorporation of non natural amino acids into proteins
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
EP1675620B1 (en) 2003-10-09 2019-05-08 Ambrx, Inc. Polymer derivatives
EP2327724A3 (en) 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
MX2014014951A (es) * 2012-06-06 2015-03-13 Oncomed Pharm Inc Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
CA2902739C (en) 2013-03-15 2022-11-22 Xencor, Inc. Heterodimeric proteins
CA2916681A1 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
AU2015305754B2 (en) 2014-08-19 2018-10-25 Merck Sharp & Dohme Llc Anti-tigit antibodies
CN107207594B (zh) 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
US10227408B2 (en) * 2015-02-19 2019-03-12 Compugen Ltd. Anti-PVRIG antibodies and methods of use
EP3344657A1 (en) 2015-09-02 2018-07-11 The Regents of the University of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
PL3356413T3 (pl) 2015-10-01 2022-04-19 Potenza Therapeutics, Inc. Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania
WO2017152088A1 (en) 2016-03-04 2017-09-08 JN Biosciences, LLC Antibodies to tigit
SI3468586T1 (sl) 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
CN110088132B (zh) 2016-08-17 2020-10-27 康姆普根有限公司 抗tigit抗体，抗pvrig抗体及其组合
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN110799213A (zh) * 2017-06-01 2020-02-14 康姆普根有限公司 三联组合抗体疗法
KR102185854B1 (ko) 2017-09-09 2020-12-02 애플 인크. 생체측정 인증의 구현

Also Published As

Publication number Publication date
AU2019276578A1 (en) 2021-01-14
US20190382477A1 (en) 2019-12-19
SG11202011461TA (en) 2020-12-30
JP2024150470A (ja) 2024-10-23
JP2021525087A (ja) 2021-09-24
JP7646361B2 (ja) 2025-03-17
EP3802605A1 (en) 2021-04-14
BR112020024249A2 (pt) 2021-03-02
CA3101019A1 (en) 2019-12-05
CN113039202A (zh) 2021-06-25
WO2019232484A9 (en) 2021-05-06
WO2019232484A1 (en) 2019-12-05
KR20210016448A (ko) 2021-02-15
IL279053A (en) 2021-01-31
CL2020003127A1 (es) 2021-10-29
CO2020016619A2 (es) 2021-01-18

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020551923A1 (en) Methods and compositions for treating cancer
ZA202201874B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12020552229A1 (en) Il-11ra antibodies
ZA201906832B (en) Novel psma-binding agents and uses thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MY203971A (en) Anti-lag-3 antibodies and compositions
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
MX2019007021A (es) Anticuerpos il-11ra.
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
CR20200088A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
MX2021003180A (es) Métodos y kits para preparar sangre entera con inactivación de patógenos.
PH12019502694A1 (en) Anti-trkb antibodies
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
WO2019143883A3 (en) Compositions and methods for the treatment of cancer
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.